Back to companies

Syndax Pharmaceuticals Inc: Overview

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

Select Item

Syndax Pharmaceuticals Inc (Syndax) is a commercial-stage biopharmaceutical company That develops advanced innovative therapies for cancer. The company pipeline products include AUGMENT-101-2A for the treatment of relapsed or refractory acute leukemia; AUGMENT-101-2C which treats relapsed or refractory NPM1-mutated acute myeloid leukemia; EVOLVE-2 for acute myeloid leukemia; REVEAL-ND, BEAT-AML, 7+3, SAVE and INTERCEPT targets relapsed or refractory and frontline NPM1m; AGAVE-201 treats refractory chronic graft-versus-host disease; and others. It operates in the Netherlands and the US. Syndax is headquartered in New York, the US.

 Gain a 360-degree view of Syndax Pharmaceuticals Inc and make more informed decisions for your business Gain a 360-degree view of Syndax Pharmaceuticals Inc and make more informed decisions for your business Register your interest
Headquarters United States of America
Address 730 Third Avenue, 9th Floor, New York City, 10017
Website www.syndax.com
Telephone 1 781 4191400
No of Employees 298
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange SNDX (NASD)
Revenue (2024) $172.4M 627.8% (2024 vs 2023)
EPS XYZ
Net Income (2024) XYZ 10.5% (2024 vs 2023)
Market Cap* $1.7B
Net Profit Margin (2024) XYZ 87.7% (2024 vs 2023)
* As of and is in US$
View Syndax Pharmaceuticals Inc financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Register your interest

Syndax Pharmaceuticals Inc premium industry data and analytics

70+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Syndax Pharmaceuticals Inc’s relevant decision makers and contact details.

50+

Clinical Trials

Determine Syndax Pharmaceuticals Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

50+

Catalyst Calendar

Proactively evaluate Syndax Pharmaceuticals Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

12+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

5

Pipeline Drugs

Identify which of Syndax Pharmaceuticals Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

3

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

Products and Services

Products Brands
Pipeline Revuforj
Revuforj (revumenib): Relapsed or Refractory Acute Leukemia Niktimvo
AUGMENT-101-2C: Relapsed or Refractory NPM1-mutated Acute Myeloid Leukemia
XYZ
XYZ
XYZ
Understand Syndax Pharmaceuticals Inc portfolio and identify potential areas for collaboration Understand Syndax Pharmaceuticals Inc portfolio and identify potential areas for collaboration Register your interest
Image for loader

Competitor Comparison

Key Parameters Syndax Pharmaceuticals Inc Vertex Pharmaceuticals Inc Alnylam Pharmaceuticals Inc Madrigal Pharmaceuticals Inc Kura Oncology Inc
Headquarters United States of America United States of America United States of America United States of America United States of America
City New York City Boston Cambridge West Conshohocken San Diego
State/Province New York Massachusetts Massachusetts Pennsylvania California
No. of Employees 298 6,400 2,500 915 260
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Register your interest
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Register your interest
Executives
Name Position Board Since Age
Dennis G Podlesak Chairman Executive Board 2008 68
Michael A Metzger Chief Executive Officer; Director Executive Board 2022 55
Keith A. Goldan Chief Financial Officer Senior Management 2022 55
Anjali Ganguli, Ph.D. Chief Strategy Officer Senior Management 2024 -
Kevin McManus Chief People Officer Senior Management - -
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Gain insight into Syndax Pharmaceuticals Inc key executives to enhance your sales strategy Gain insight into Syndax Pharmaceuticals Inc key executives to enhance your sales strategy Register your interest
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Why are you leaving?